Recent progress in therapeutic antibodies for cancer immunotherapy. (June 2018)

• Record Type: Journal Article
• Authors: Lee, Anthony; Sun, Shawn; Sandler, Alan; Hoang, Tien
• Is Part Of: Current opinion in chemical biology. Volume 44(2018)
• Page Start: 56
• Page End: 65
• Publication Date: 2018-06
• Subjects: Bioorganic chemistry -- Periodicals; Biology -- Periodicals; Biochemistry -- Periodicals; Clinical biochemistry -- Periodicals; Biochemistry -- Periodicals; Chimie bio-organique -- Périodiques; Biologie -- Périodiques; 572.05
• DOI: 10.1016/j.cbpa.2018.05.006
• Languages: English
• ISSNs: 1367-5931

Abstract

Highlights: There is a heavy focus of clinical cancer research efforts on cancer immunotherapy. Treatment with checkpoint inhibitors has shown to improve standard of care. Immune escape mechanisms may involve different immune phenotypes. Biomarkers include PD-L1 expression, gene signatures, and tumor mutation burden. New combinations and bi-specific antibody technologies are being developed. Abstract : Therapeutic antibodies have advanced the clinical management of multiple diseases including cancer. Cancer immunotherapy has been a focal point of recent clinical research with the success of checkpoint inhibitor antibodies, particularly those that target the PD-L1/PD-1 pathway. These antibodies that target specific steps of the cancer-immunity cycle show improved anti-tumor response, progression-free survival and overall survival versus standard therapy across multiple tumor types. Despite these advancements, not all patients experience durable response from checkpoint inhibition treatment. Ongoing research is focused on identifying various biomarkers of cancer-immune biology and elucidating specific immune escape mechanisms. Additionally, current clinical development efforts have focused on checkpoint inhibitors in combination with other agents as well as developing new antibody technologies targeting different targets simultaneously.